glp-1 agonist. receptor agonists show promise in treating substance use disorders Glucagon-like peptide-1 - Wikipedia

Always check with your insurance provider to understand your coverage

To assess heterogeneity, Chi-square and I 2 statistics were utilized, with significant heterogeneity defined as a p -value below 0.1 and an I 2 exceeding 50%

doi: 10.3390/ijms20174092 [DOI] [PMC free article] [PubMed] [Google Scholar] 14.Nauck MA, Quast DR, Wefers J, Meier JJ

Those who completed the full 48 weeks averaged significantly better outcomes than those who discontinued early, reinforcing the importance of persistence through the challenging adaptation period

[DOI] [PubMed] [Google Scholar] 9

In recent years, research has shown that GLP-1s may help with a variety of conditions, including obstructive sleep apnea, heart disease, and chronic kidney disease